Shilpa Medicare Limited, a prominent pharmaceutical and biotechnology company headquartered in India, has announced a strategic partnership between its wholly owned subsidiary Shilpa Biocare Private Limited and Orion Corporation, a leading pharmaceutical company based in Finland. This partnership focuses on the commercialisation of Shilpa’s flagship product Recombinant Human Albumin in the European market.

Under this agreement, Orion Corporation will hold exclusive rights for the distribution, marketing, and sales of recombinant human albumin in Europe. Shilpa Medicare will receive milestone payments linked to development and regulatory achievements from Orion reflecting the product’s advancement stage.

Recombinant Human Albumin is a crucial plasma protein widely used in various therapeutic applications and as an essential ingredient in vaccine and biologics manufacturing. Unlike traditional human-derived albumin, Shilpa’s product is developed using a robust non-human expression system ensuring high safety standards, virus-free production, and scalable manufacture. This innovation addresses key limitations associated with human-derived albumin making it a safer and more reliable biologic product.

Shilpa Medicare has invested around eight years in developing this novel recombinant product and established a large-scale fermentation facility capable of meeting global market demand for this life-saving drug. The collaboration with Orion is a major milestone leveraging Orion’s extensive regional presence, regulatory expertise, and commercial infrastructure to accelerate access to the European market.

Madhav Bhutada, Managing Director of Shilpa Biocare, stated partnering with Orion is a significant step towards delivering our innovative recombinant human albumin to patients across Europe. This alliance validates our capabilities and aligns with our mission to provide high-quality and affordable biologics globally.

Orion Corporation’s EVP of Generics and Consumer Health, Satu Ahomäki, added this collaboration strengthens our portfolio in hospital generics and supports our strategy to bring value-added biologics to European patients.

The partnership reinforces both companies’ commitment to advancing biotechnology-driven therapies and improving patient access to next-generation biologics that are safer, more sustainable, and scalable.

About Shilpa Medicare Limited
Shilpa Medicare is a diversified pharmaceutical company focused on complex generics, biologics, and active pharmaceutical ingredients APIs. The company is recognized for innovation, quality, and affordability in global healthcare.

About Orion Corporation
Orion is a Nordic pharmaceutical company with a century-long legacy in human and veterinary pharmaceuticals. It specializes in oncology, pain management, neurological, and respiratory diseases. Orion’s shares are listed on Nasdaq Helsinki with net sales of EUR 1,542 million in 2024.

The Upcoming IPOs in this week and coming weeks are Scoda Tubes,Neptune Petrochemicals, Aegis Vopak Terminals, Schloss Bangalore, Astonea Labs, Nikita Papers, Prostarm Info Systems, Victory Electric Vehicles International, Blue Water Logistics, Wagons Learning.

The Current active IPO are Unified Data - Tech Solutions, Dar Credit and Capital, Belrise Industries.

The Closed IPOs are Borana Weaves.